EGFR targeted therapy in non-small cell lung cancer: Potential role of cetuximab

Chad A. Reade, Apar Kishor P Ganti

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Chemotherapy alone has limited ability to significantly improve survival in non-small lung cancer (NSCLC) beyond what has already been achieved. The epidermal growth factor (EGF) pathway plays a vital role in the pathogenesis and progression of NSCLC. Two classes of drugs inhibit the EGF receptor (EGFR) pathway: small molecules that inhibit the intracellular tyrosine kinase activity of the receptor, and monoclonal antibodies that target the extracellular domain in the ligand-binding region. Cetuximab is a human - mouse chimeric immunoglobulin G1 class monoclonal antibody directed against EGFR. Preclinical studies with cetuximab suggested that there was inhibition of growth of human NSCLC cell lines. Cetuximab is currently the focus of intense investigation in various patient populations with NSCLC. This review focuses on clinical trials of cetuximab in NSCLC and identifies future directions with this agent.

Original languageEnglish (US)
Pages (from-to)215-224
Number of pages10
JournalBiologics: Targets and Therapy
Volume3
DOIs
StatePublished - Jan 1 2009

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Monoclonal Antibodies
Immunoglobulin Isotypes
Receptor Protein-Tyrosine Kinases
Therapeutics
Epidermal Growth Factor
Lung Neoplasms
Clinical Trials
Ligands
Drug Therapy
Cell Line
Survival
Cetuximab
Growth
Pharmaceutical Preparations
Population

Keywords

  • Cetuximab
  • EGFR
  • Monoclonal antibodies
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Oncology
  • Gastroenterology
  • Pharmacology (medical)

Cite this

EGFR targeted therapy in non-small cell lung cancer : Potential role of cetuximab. / Reade, Chad A.; Ganti, Apar Kishor P.

In: Biologics: Targets and Therapy, Vol. 3, 01.01.2009, p. 215-224.

Research output: Contribution to journalReview article

@article{2134b34bca89403a9907c54ded7c2e24,
title = "EGFR targeted therapy in non-small cell lung cancer: Potential role of cetuximab",
abstract = "Chemotherapy alone has limited ability to significantly improve survival in non-small lung cancer (NSCLC) beyond what has already been achieved. The epidermal growth factor (EGF) pathway plays a vital role in the pathogenesis and progression of NSCLC. Two classes of drugs inhibit the EGF receptor (EGFR) pathway: small molecules that inhibit the intracellular tyrosine kinase activity of the receptor, and monoclonal antibodies that target the extracellular domain in the ligand-binding region. Cetuximab is a human - mouse chimeric immunoglobulin G1 class monoclonal antibody directed against EGFR. Preclinical studies with cetuximab suggested that there was inhibition of growth of human NSCLC cell lines. Cetuximab is currently the focus of intense investigation in various patient populations with NSCLC. This review focuses on clinical trials of cetuximab in NSCLC and identifies future directions with this agent.",
keywords = "Cetuximab, EGFR, Monoclonal antibodies, Non-small cell lung cancer",
author = "Reade, {Chad A.} and Ganti, {Apar Kishor P}",
year = "2009",
month = "1",
day = "1",
doi = "10.2147/BTT.S4479",
language = "English (US)",
volume = "3",
pages = "215--224",
journal = "Biologics: Targets and Therapy",
issn = "1177-5475",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - EGFR targeted therapy in non-small cell lung cancer

T2 - Potential role of cetuximab

AU - Reade, Chad A.

AU - Ganti, Apar Kishor P

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Chemotherapy alone has limited ability to significantly improve survival in non-small lung cancer (NSCLC) beyond what has already been achieved. The epidermal growth factor (EGF) pathway plays a vital role in the pathogenesis and progression of NSCLC. Two classes of drugs inhibit the EGF receptor (EGFR) pathway: small molecules that inhibit the intracellular tyrosine kinase activity of the receptor, and monoclonal antibodies that target the extracellular domain in the ligand-binding region. Cetuximab is a human - mouse chimeric immunoglobulin G1 class monoclonal antibody directed against EGFR. Preclinical studies with cetuximab suggested that there was inhibition of growth of human NSCLC cell lines. Cetuximab is currently the focus of intense investigation in various patient populations with NSCLC. This review focuses on clinical trials of cetuximab in NSCLC and identifies future directions with this agent.

AB - Chemotherapy alone has limited ability to significantly improve survival in non-small lung cancer (NSCLC) beyond what has already been achieved. The epidermal growth factor (EGF) pathway plays a vital role in the pathogenesis and progression of NSCLC. Two classes of drugs inhibit the EGF receptor (EGFR) pathway: small molecules that inhibit the intracellular tyrosine kinase activity of the receptor, and monoclonal antibodies that target the extracellular domain in the ligand-binding region. Cetuximab is a human - mouse chimeric immunoglobulin G1 class monoclonal antibody directed against EGFR. Preclinical studies with cetuximab suggested that there was inhibition of growth of human NSCLC cell lines. Cetuximab is currently the focus of intense investigation in various patient populations with NSCLC. This review focuses on clinical trials of cetuximab in NSCLC and identifies future directions with this agent.

KW - Cetuximab

KW - EGFR

KW - Monoclonal antibodies

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=77949409277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949409277&partnerID=8YFLogxK

U2 - 10.2147/BTT.S4479

DO - 10.2147/BTT.S4479

M3 - Review article

AN - SCOPUS:77949409277

VL - 3

SP - 215

EP - 224

JO - Biologics: Targets and Therapy

JF - Biologics: Targets and Therapy

SN - 1177-5475

ER -